Alembic Pharmaceuticals533573Pharmaceuticals
Alembic Pharma reported strong Q2 results with revenue up 36%, profit up around 81% and sharp improvement in EBITDA margins, driven by US formulations growth
By ScoutQuest · · 1 min read
- Revenue growth
- 36 percent
- EBITDA margin
- 21.6 percent
- Prior year EBITDA margin
- 16.5 percent
- US formulations growth
- 77 percent
- US formulations revenue
- 1,000 crore rupees
Heard on business television between 15:42:54 - 15:45:54 IST.
- Revenue was up 36% year-on-year.
- Profit was up around 81% year-on-year.
- EBITDA margins came in at around 21.6% versus 16.5% a year ago.
- US formulations business, a key driver, grew 77% year-on-year to a little over 1,000 crore rupees.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Alembic Pharmaceuticals
Alembic Pharmaceuticals submits audio recording of 4th November, 2026 post results conference call
4 Nov 2026
Updated contact details of KMP authorised to decide materiality and make disclosures
4 Nov 2026
Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals for its US complex generics portfolio
4 Nov 2026
Source: Live TV News Channel · 4 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.